Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joel Charrow

Showing results (51-60 of 110) with videos related to

Pageof 11
Sort By:
American Journal of Hematology|October 26, 2005
Guidance on the use of miglustat for treating patients with type 1 Gaucher diseaseNeal J Weinreb, John A Barranger, Joel Charrow, et al.
American Journal of Hematology|May 22, 2020
Real-world effectiveness of eliglustat in treatment-naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher RegistryPramod K Mistry, Manisha Balwani, Joel Charrow, et al.
American Journal of Medical Genetics. Part A|February 10, 2026
Rising Inpatient Demands for Inherited Metabolic Disorders: Impact on Pediatric CapacityMaria Paula Silva, Kirsten Havens, Katherine Arduini, et al.
Journal of Inherited Metabolic Disease|September 15, 2012
Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatmentNeal J Weinreb, Jack Goldblatt, Jacobo Villalobos, et al.
Molecular Genetics and Metabolism|November 24, 2023
Treatment-naive and post-treatment glucosylsphingosine (lyso-GL1) levels in a cohort of pediatric patients with Gaucher diseaseCarly A Rasmussen, Allegra Quadri, Erika Vucko, et al.
Molecular Genetics and Metabolism|September 22, 2015
Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United StatesManisha Balwani, Thomas Andrew Burrow, Joel Charrow, et al.
Molecular Genetics and Metabolism|September 12, 2016
Home infusion of intravenous velaglucerase alfa: Experience from pooled clinical studies in 104 patients with type 1 Gaucher diseaseDeborah Elstein, T Andrew Burrow, Joel Charrow, et al.
The Journal of Molecular Diagnostics : JMD|July 22, 2022
Utility and Outcomes of the 2019 American College of Medical Genetics and Genomics-Clinical Genome Resource Guidelines for Interpretation of Copy Number Variants with Borderline Classifications at an Academic Clinical Diagnostic LaboratoryAndy Drackley, Casey Brew, Alissa Wlodaver, et al.
Molecular Genetics and Metabolism|February 28, 2012
Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cellsSuhrad G Banugaria, Trusha T Patel, Joanne Mackey, et al.
Journal of Medical Genetics|October 23, 2015
Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapyDavid G Warnock, Christie P Thomas, Bojan Vujkovac, et al.
Pageof 11

Showing results (51-60 of 110) with videos related to

Sort By:
Pageof 11
American Journal of Hematology|October 26, 2005
Guidance on the use of miglustat for treating patients with type 1 Gaucher diseaseNeal J Weinreb, John A Barranger, Joel Charrow, et al.
American Journal of Hematology|May 22, 2020
Real-world effectiveness of eliglustat in treatment-naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher RegistryPramod K Mistry, Manisha Balwani, Joel Charrow, et al.
American Journal of Medical Genetics. Part A|February 10, 2026
Rising Inpatient Demands for Inherited Metabolic Disorders: Impact on Pediatric CapacityMaria Paula Silva, Kirsten Havens, Katherine Arduini, et al.
Journal of Inherited Metabolic Disease|September 15, 2012
Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatmentNeal J Weinreb, Jack Goldblatt, Jacobo Villalobos, et al.
Molecular Genetics and Metabolism|November 24, 2023
Treatment-naive and post-treatment glucosylsphingosine (lyso-GL1) levels in a cohort of pediatric patients with Gaucher diseaseCarly A Rasmussen, Allegra Quadri, Erika Vucko, et al.
Molecular Genetics and Metabolism|September 22, 2015
Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United StatesManisha Balwani, Thomas Andrew Burrow, Joel Charrow, et al.
Molecular Genetics and Metabolism|September 12, 2016
Home infusion of intravenous velaglucerase alfa: Experience from pooled clinical studies in 104 patients with type 1 Gaucher diseaseDeborah Elstein, T Andrew Burrow, Joel Charrow, et al.
The Journal of Molecular Diagnostics : JMD|July 22, 2022
Utility and Outcomes of the 2019 American College of Medical Genetics and Genomics-Clinical Genome Resource Guidelines for Interpretation of Copy Number Variants with Borderline Classifications at an Academic Clinical Diagnostic LaboratoryAndy Drackley, Casey Brew, Alissa Wlodaver, et al.
Molecular Genetics and Metabolism|February 28, 2012
Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cellsSuhrad G Banugaria, Trusha T Patel, Joanne Mackey, et al.
Journal of Medical Genetics|October 23, 2015
Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapyDavid G Warnock, Christie P Thomas, Bojan Vujkovac, et al.
Pageof 11